You will be redirected to:
Today, September 21st, is the World Alzheimer’s Day, so let’s do a quick review of the investigated therapeutic targets to find a cure to this pathology: Alzheimer’s disease is the most common form of dementia with approximatively 9.7 millions of patients in Europe. Its 2 main hallmarks in the brain are: amyloid-β (Aβ) plaques, and tau-proteins neurofibrillary tangles.
Logically, investigated treatments are aiming to act on either the Aβ or the tau proteins, to avoid the apparition of these undesired supramolecular aggregates. On the Aβ side, most of the therapeutic approaches to reduce the accumulation of the protein have shown very few clinical outcomes… Some researchers have even come to consider that Aβ disorders might be only a consequence of Alzheimer’s disease, and not a cause.
However, immunotherapies targeting Aβ-oligomers appear to have promising clinical results, in asymptomatic/mild stages of the disease to prevent the apparition of more symptoms, showing that the role of Aβ in the Alzheimer’s disease apparition and evolution is not fully understood, yet.
On the tau protein side, the relation between a malfunction in the tau-protein cycle and the neurologic symptoms appears quite robust, as clinical results have shown an important correlation between tau burden and patients’ symptoms. However, as tau also plays an important role in the normal functioning of the whole brain, tau-targeting approaches may be impaired by important side-effects…
For that reason, the tau-targeting most promising trials are immunotherapies focusing specifically the mutant tau-proteins, causing the disease. To go further on the understanding of Alzheimer’s disease, and the treatments investigated, check those excellent reviews:
Stay updated on the latest articles, events, and more
Nowadays, all companies active in the life science ecosystem consider data as a crucial asset to their success. Pharma companies are collecting more and more information during their clinical trials or commercial and medical activities. Clinical laboratories have to deploy complex data infrastructures to better serve their patients and clients, and Biotech and MedTech companies need to gather and analyze a lot of scientific and technical data.
Paris 9th January, 2023 (France) - Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the international Connected Contract Research Organization (C²RO), announced the signing of a strategic partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities.
Paris, Levallois-Perret, November 7th, 2022 - Keyrus Life Science and Parean Biotechnologies will join their expertise in data science and technologies to meet the most critical challenges for clients in the fields of biometry, biostatistics and bioinformatics.
This summer was very busy and interesting for the Keyrus Life Science North America Team. We attended three pivotal life science conferences: Decentralized Clinical Trials Conference, BIO International Convention, and DIA Conference.
Paris, Levallois-Perret, June 23, 2022 - Keyrus Life Science announces the launch of its new visual identity strengthening its synergies with the Keyrus Group to address the most pressing challenges of its clients in the life science industry and to drive clinical research forward.
Digitalization, data and connectivity has become part of our daily lives in all its dimensions.
Clinical trials produce a massive amount of data. In most cases, the challenge lies less in the volume of data to process, but more in its diversity. The sources of data are indeed numerous and do not stop increasing.
The World Heart Day, an occasion to remind us all, that cardiovascular diseases (CVD) causes more than 18 million of deaths per year.
Keyrus Life Science joined the Keyrus Foundation in the team sports challenge 'Connected against hunger'
We are happy to have partnered with European Centre for Clinical Research Training (ECCRT) in training our experts at Keyrus Life Science.